Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19880564 | 0.84 | P2RY1 (0.36) | MAPK1NLRP3P2RY1RECQLSMN1; SMN2 | |
| SCHEMBL23491169 | 0.84 | MAPK1 (0.36) | MAPK1ACACBCYP3A4AAK1 | |
| SCHEMBL19779578 | 0.80 | AGBL2 (0.45) | MAPK1SMN1; SMN2 | |
| SCHEMBL19779577 | 0.77 | L3MBTL1 (0.37) | MAPK1 | |
| SCHEMBL22096834 | 0.76 | MAPK1 (0.38) | MAPK1AAK1P2RY1SMN1; SMN2 | |
| SCHEMBL26239679 | 0.74 | JAK2 (0.35) | MAPK1SMN1; SMN2LMNA | |
| SCHEMBL19768974 | 0.72 | RECQL (0.40) | MAPK1NLRP3P2RY1RECQLSMN1; SMN2 | |
| SCHEMBL19769042 | 0.72 | P2RX3 (0.38) | MAPK1CYP3A4LMNA | |
| SCHEMBL22852740 | 0.70 | MKNK2 (0.42) | P2RY1RECQLSMN1; SMN2LMNA | |
| SCHEMBL23491168 | 0.70 | MAPK1 (0.34) | MAPK1AAK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | MAPK1 2655/4885ACACB 4059/4885NLRP3 3808/4885 |
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | MAPK1 2655/4885ACACB 4059/4885NLRP3 3808/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | MAPK1 2655/4885ACACB 4059/4885NLRP3 3808/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | MAPK1 2655/4885ACACB 4059/4885NLRP3 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.